Skip to main content

All-Cause Mortality Risk Up for Men With Low Testosterone

Medically reviewed by Carmen Pope, BPharm. Last updated on May 14, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, May 13, 2024 -- The risk for all-cause mortality is increased for men with low testosterone, high luteinizing hormone, or very low estradiol, according to a review published online May 14 in the Annals of Internal Medicine.

Bu B. Yeap, M.B.B.S., Ph.D., from the University of Western Australia in Perth, and colleagues conducted a systematic review to clarify associations of sex hormones with mortality and cardiovascular disease (CVD). Nine studies provided individual participant data (IPD; 255,830 participant-years), and summary estimates were provided by 11 studies (24,109 participants).

The researchers found that two-stage random-effects IPD meta-analyses indicated higher all-cause mortality for men with baseline testosterone concentrations below 7.4 nmol/L, luteinizing hormone concentrations above 10 IU/L, or estradiol concentrations below 5.1 pmol/L; higher CVD mortality risk was seen for those with testosterone concentrations below 5.3 nmol/L. Lower sex hormone-binding globulin concentration was associated with lower all-cause and CVD mortality (adjusted hazard ratios, 0.85 and 0.81, respectively, for quintile 1 versus 5). Higher risk for all-cause and CVD mortality was seen for men with lower baseline dihydrotestosterone concentrations (adjusted hazard ratios, 1.19 and 1.29, respectively, for quintile 1 versus 5); risk increased with concentrations above 2.45 nmol/L. An increased risk for incident CVD events was seen for men with dihydrotestosterone concentrations below 0.59 nmol/L.

"We found that the testosterone concentration below which men had higher risk for all-cause mortality was 7.4 nmol/L (213 ng/dL)," the authors write. "This adds to information on reference ranges based on distributions of testosterone in selected samples of healthy men."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

2024 ASCO Annual Meeting to Focus on Clinical Cancer Research Impacting Patient Care

THURSDAY, May 23, 2024 -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held May 31 to June 4, 2024, in Chicago and online. The theme of this...

Socioeconomic Status Transitions Tied to Dementia Risk

THURSDAY, May 23, 2024 -- Upward and downward socioeconomic status (SES) transitions are associated with the risk for dementia and the length of dementia-free periods during the...

4-Dimensional Model Can Predict Lymph Node Metastases in Breast Cancer

THURSDAY, May 23, 2024 -- A deep learning model using tumor dynamic contrast-enhanced breast magnetic resonance imaging (MRI) has high sensitivity for identifying lymph node...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.